I’ll be honest. TV commercials that cite “low T” and the benefits of testosterone therapy made me suspect of hypogonadism in men. It didn’t help my cynicism watching sports stars “juicing” to achieve records or extend their careers. However, the studies cited in the blog posts linked below as well as the study linked at the bottom of the page document specific benefits of testosterone therapy for hypogonadal men.
If you are 1) obese and 2) hypogonadal, consider testosterone therapy (TT). While TT is not a quick fix, the study linked below followed men over ten years, testosterone therapy
And there is no evidence of adverse events. In fact, the TT group compared to the control group had fewer heart attacks, fewer strokes, less prostate cancer and fewer deaths overall.
I wouldn’t normally be blogging about testosterone therapy and obese men. However in the past two weeks I have written about TT therapy for other health issues-
The top blog post in the recommended reading section below spells out the many health problems when men alter their testosterone. However, after reading the studies about the health challenges caused by low T, it is clear that hypogonadism is a legitamate health problem that can and should be addresses. Do so only under the supervision of a medical physician.
To learn more about hypogonadism, scroll down the page, post a question or comment and I will reply to you ASAP.
“Objective: To evaluate risk of prostate cancer biochemical recurrence (BCR) after radical prostatectomy (RP) in men receiving vs not receiving testosterone replacement therapy (TRT)…
Conclusion: In our experience, TRT after RP significantly reduced BCR and delayed time to BCR. There was no identifiable general health complications associated with TRT. These findings are hypothesis-generating and require confirmation with multi-centred, prospective randomised controlled trials…”
“Men who receive testosterone replacement therapy had an increased rate of favorable-risk prostate cancer compared to those who did not use the therapy, and a decreased rate of aggressive prostate cancer.
Men who receive testosterone replacement therapy (TRT) had an increased rate of favorable-risk prostate cancer compared to those who did not use the therapy, and a decreased rate of aggressive prostate cancer. The favorable risk disease may represent a detection bias in these patients, according to the researchers…”
“Long-term testosterone therapy may not only help men with obesity and hypogonadism to lose weight, but it may have other useful effects on metabolic function and protect against obesity comorbidities, according to a presentation at the Androgen Society annual meeting…
Traish presented the findings of a prospective registry study of 805 men with hypogonadism (mean age, 59 years) and their responses to testosterone therapy in relation to obesity and other metabolic measures. Weight status was varied in the total cohort, with 462 men with obesity, 280 with overweight and 63 with normal weight. A total of 412 men, including 273 with obesity, were treated with testosterone undecanoate injections at 12-week intervals for 10 years. The other 393 participants elected to go untreated and served as a control comparison for the treatment group…
After treatment, the researchers found that there was a noticeable decrease in the percentage of weight loss from baseline, especially after 2 years, in participants with overweight and obesity compared with those who went untreated. Testosterone therapy was associated with reduced mean body weight from 97.3 kg to 84.6 kg in the cohort with decreases in waist circumference (107 cm to 92 cm) and BMI (31 kg/m2 to 27 kg/m2). In addition, testosterone therapy led to improved HbA1c, blood glucose, total cholesterol and visceral fat levels, according to Traish, who said because the study included a control group and accurate adherence since the testosterone injections were made by a physician every 3 months, “this data is really significant and important.”
The researchers also monitored adverse events in the cohort and found that there were 12 deaths, but no myocardial infarctions or strokes in the men with obesity treated with testosterone compared with 57 deaths, 47 MIs and 44 strokes in men who were untreated. The rates of prostate cancer were 2.9% in the men with obesity who were treated with testosterone and 11.1% (n = 21) in the men with obesity who were untreated, although Traish said he found slight but expected increases in hemoglobin and hematocrit in those treated with testosterone…